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Abstract. Experimental Modeling ADMA-like preeclampsia administration to rats was performed by N-
nitro-L-arginine methyl ester, from 14 to 20 days of pregnancy. The animals were observed increase in 
blood pressure, proteinuria, impaired microcirculation in the placenta, the violation of the regulation of 
vascular tone and destructive changes in the placenta of ischemic origin. Introduction of 
tetrahydrobiopterin, a selective inhibitor of arginase II of, recombinant erythropoietin, tadalafil, 
erythromycin, azithromycin, and playback systems polivitaminnomineralnyh distant ischemic 
preconditioning resulted in a pronounced correction of morphological and functional disorders arise 
when modeling the experimental preeclampsia. This was reflected in the reduction of blood pressure, 
reduction of proteinuria, increase of microcirculation in the placenta, the restoration of vasodilator 
function of blood vessels and prevent destructive phenomena in the placenta compared with a group of 
untreated animals, increasing the concentration of NO end-metabolites in plasma. These data suggest a 
pronounced correction of morphological and functional disorders arise when modeling ADMA-like 
preeclampsia study medication and the prospects for further research to find new drugs have 
endoteleoprotektivnymi properties for correcting the second half of pregnancy preeclampsia. 
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INTRODUCTION 
Preeclampsia is the most common obstetric 
pathology. In certain regions of the country, its 
frequency can be more than 30% of all cases of 
pregnancy [1, 2]. In preeclampsia maternal mortality 
is one of the first places. It accounts for up to 25% of 
cases [3, 4]. Children born to mothers who have had 
preeclampsia, perinatal morbidity is 30%, and the 
mortality rate is 3-4 times higher than the population-
based [5]. In addition, suffering mental and physical 
development of the child, while women are more 
likely development of chronic kidney disease and 
hypertension [4, 6]. 
The pathogenesis of preeclampsia is still far from a 
complete understanding, but more and more researchers 
are paying attention disangiogenesis in the placenta and 
impaired regulation of the tone of small arteries [7, 8, 
9]. A morphological study of the placenta, many 
authors describe a specific histology, which is the 
imbalances of its border area between the maternal and 
fetal parts [10, 11, 12, 13]. Incomplete cytotrophoblast 
invasion occurs in maternal spiral arteries, leading to 
ischemic events in the placenta and increase the 
permeability barrier foetoplacental [11, 14]. 
Release in the systemic circulation of the 
ischemic placenta free radicals, hormones, growth 
factors, pro-inflammatory cytokines, fetal antigens 
and other humoral factors causes an increase in the 
content of cell adhesion molecules and blood 
accumulation of endogenous inhibitors of eNOS – 
methylated analogs of L-arginine asymmetric 
dimethylarginine (ADMA) and monometilarginina 
(L-NMMA). The end finale is a complex 
pathophysiological mechanisms and a violation of the 
rheological properties of blood coagulation and 
endothelial dysfunction, which cause multiple organ 
failure [14, 15, 16]. 
Thus, at the present time it has accumulated quite a 
lot of information on the impact of various factors on 
the course of preeclampsia and their role in the 
development of endothelial dysfunction as the main 
pathogenetic link of this terrible disease and the 
possibility of correction of endothelial dysfunction 
pharmacological agents of different groups [17, 18, 19]. 
However, the available literature there is no information 
about the study endothelioprotektive action in terms of 
ADMA-like preeclampsia tetrahydrobiopterin, tadalafil, 
vitamin B6 and folic acid, multivitamins and mineral 
complexes, erythromycin, azithromycin, recombinant 
erythropoietin, as well as on the effectiveness of the 
direction, which is based on distant ischemic 
preconditioning. 
MATERIALS AND METHODS 
The experiment was performed on female white rats 
of Wistar line weighing 250-300 g ADMA-like Gesto 
modeoirovali by administration of non-selective NO-
synthase blocker of N-nitro-L-arginine methyl ester 
(L-NAME) was administered intraperitoneally in a dose 
of 25 mg / kg / day for seven days (day 14-20 of 
pregnancy) [10, 20, 21, 22]. To simulate the reduced 
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blood flow to the uterus on day 14 of gestation in 10 
animals were silver overlay clips directly above the 
bifurcation of the abdominal aorta (0.2 mm) on both 
ovarian artery (0.1 mm). In 10 animals on day 14 of 
gestation performed silver overlay clip on the right iliac 
artery (0.1 mm) and the right ovarian artery (0.1 mm) 
[23, 24]. 
The degree of endothelial dysfunction by 
calculating the ratio of endothelial dysfunction 
(CED) [10, 20]. 
The level of NO metabolites (m. E. The total 
concentration of nitrite and nitrate, NOx) was 
measured colorimetrically using a color development 
reaction diazotization of sulfanilamide nitrite forming 
part of the reagent. eNOS levels were determined in 
the cell lysate by the method of R.J. Hendrickson 
with minor modifications [10, 25]. 
Measurement of the microcirculation in the 
placenta was performed using equipment companies 
Biopacsystems: polygraph MP100 module with laser 
Doppler flowmetry (LDF) LDF100C and invasive 
needle sensor TSD144 [10, 20, 21]. 
Collection of urine was performed for 12 hours 
using a special metabolic cages. The method 
Brandberg-Roberts-Stolnikova ring is sample Geller. 
To investigate the liquid in the greater omentum 
was performed weighing it, followed by drying at 37 
0C for 24 hours and weighed again [5, 26]. 
Morphological studies were conducted under the 
guidance of prof. AA Dolzhikov and prof. VS 
Barsukov 
The embrions was removed from the uterine 
cavity, weighed, measured growth (craniocaudal size) 
followed by calculation of height-for-weight [27]. 
1. COMPARATIVE ASSESSMENT OF
MORPHOFUNCTIONAL DISTURBANCES AT 
ADMA-MODELING OF PREECLAMPSIA AND 
REDUCED BLOOD FLOW TO THE UTERUS 
With the introduction of ADMA-like agents – L-
NAME to pregnant females (25 mg / kg once daily 
from 14 to 20 days of pregnancy) on day 21 we 
observed the development of pathology in its 
manifestations corresponding criteria of clinical 
manifestations of preeclampsia. There was a 
statistically significant increase in systolic and 
diastolic blood pressure to 134,5 ± 2,3 and 92,0 ± 2,1 
to 186,3 ± 7 and 145,0 ± 5,0 mm Hg. Art., 
respectively, and an increase in CED with 1,1 ± 0,11 
to 3,12 ± 0,17 (p <0,05) (Table. 1.1). 
The value of the level of the microcirculation in 
the placenta intact pregnant rats on day 21 amounted to 
446,3 ± 27,5 ped (perfusion units). In the simulation, 
ADMA-like preeclampsia, it found a significant 
decrease to 218,3 ± 13,7 ped. In intact pregnant rats 12-
hour urine output was 5.8 ± 0.3 ml, which corresponded 
to the normal performance of animals weighing 250-
300 g at proteinuria, which values correspond to 0.93 ± 
0.06 g / l, ie to 1.0 g / l. The introduction of L-NAME 
had no significant effect on 12-hour urine output. In the 
analysis of urine revealed a moderately pronounced 
increase in proteinuria with values of 2,04 ± 0,22 g / l (p 
<0,05). However, it should be noted that in the 
measurement of the microcirculation in the renal tissue 
is statistically significant difference between the group 
of intact animals, and pregnant animals with simulated 
ADMA-like preeclampsia was not observed. 
Examination of endothelial NO-producing 
function showed that the simulation L-NAME-
induced deficit of NO resulted in a sharp decrease in 
expression of eNOS and content of nitrite ion (NOx), 
respectively, 1.8 and 1.7-fold (Table 1.1.). 
Histology of the kidneys intact pregnant rats (21 
days gestation) were as follows: glomeruli moderately 
congested, the basement membrane is thickened, 
inflammatory changes in the interstitium and glomeruli 
are no pyramids; spastic and hypertrophic changes in 
the small arteries and arterioles were detected (Fig. 1.1). 
Figure 1.1. Kidney pregnant rats normal: small artery in the 
cortex is intact with no signs of hypertrophy of the walls, its 
endothelium; glomerular capillary basement membrane is 
thickened, the cellular inflammatory response is absent. H & 
E stain. X 280. 
Placenta rats on day 21 of pregnancy with no 
signs of damage (Fig. 1.2). 
In rats with ADMA-like preeclampsia found to 
increase the fluid content in the tissue of the greater 
omentum with 49,89 ± 0,82% to 58,09 ± 1,73% 
(p <0.05). The glomeruli showed signs of ischemic 
damage in the form of anemia, and degenerative 
changes in the basal membrane of the glomerular 
capillaries with thickened in its form of wire loops (Fig. 
1.3 (b)). A notable reaction mesangium were observed: 
the average number of cells per glomerulus was 39.20 ± 
2.99 (40.70 ± 3.80 normally). These changes may 
explain the glomerular apparatus available to the rats in 
this group hyperfiltration with severe proteinuria. In the 
small arteries and arterioles spasm observed and 
marked hypertrophy of the walls (Fig. 1.3 (a)). 
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Figure 1.2. The structure of an intact placenta. spongy structure (villous) layer (a) and the border area between naps and a layer 
of giant trophoblast (b) of the placenta intact animals: uniform blood circulation capillaries of the villi and mezhkapillyarnyh 
spaces, relatively monomorphic structure trophoblast, the continuity of the transition from villous trophoblastic layer in the 
layer; Ochre. hematoxylin and eosin. Fig-. X 200 
Figure 1.3. Kidney of pregnant rats with preeclampsia (pregnancy day 21). and – a spasm and hypertrophy of arterioles;  
b – a ball of anemia, capillary basement membrane thickened dramatically and have the form of wire loops (membranous 
glomerulopathy); Ochre. hematoxylin and eosin. Fig-. X 280 
Morphology of the placenta at ADMA-like 
preeclampsia manifested as ischemia villi and 
intervilleznyh spaces and desquamation of the 
endothelium in the vessels of the placenta (Fig. 1.4). 
In some cases, this resulted in the emergence of 
necrosis of decidual cells of placenta tissue. On the 
outer surface of the placenta was observed massive 
deposits of fibrin. 
А 
Б 
А Б 
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Figure 1.4. Pathological changes in the placenta in modeling ADMA-like preeclampsia. A – uneven blood filling spongy layer; 
B – vacuolar degeneration of giant trophoblast; foci of necrosis on the border of giant trophoblast and decidua tissue; 
degenerative changes, anemia decidual layer. Ochre. hematoxylin and eosin. Fig-. X 200. 
Silver overlay clips above the aortic bifurcation 
and 2 ovarian artery led to a rise in blood pressure up 
to 155,4 ± 3,6 and 109,3 ± 5,7 mm Hg. Art. Factor of 
endothelial dysfunction increased to 2,02 ± 0,23 (p 
<0,05). In addition, there was a decrease of 
microcirculation in the placenta of both uterine horns 
to 229,7 ± 9,9 446,3 ± 27,5 at ped in intact pregnant 
females. Simulation of blood flow reduction in both 
uterine horns resulted in a statistically significant as 
compared to intact pregnant animals increase in 
proteinuria to 1,34 ± 0,11 g / l (p <0,05). 
NO-producing endothelial function tests in 
animals with reduced blood flow in both uterine 
horns showed no statistically significant difference in 
the expression of eNOS and endothelial final 
concentration of NO metabolites in blood plasma 
compared with intact pregnant animals. 
In the simulation, the reduced blood flow in both 
uterine horns in the placenta were observed 
pronounced changes in ischemic (Fig. 1.5). 
Overlay clip on the artery supplying the right 
uterine horn only led to a decrease in 
microcirculation in the placenta right before the horn 
and 204,4 ± 14,3 to 309,0 ± 15,8 ped in the left horn 
of the uterus (p <0,05). No statistically significant 
changes in blood pressure, CED, diuresis, proteinuria 
and NO – synthesizing endothelial function have 
been identified in these animals. 
In the simulation, the reduced blood flow in the 
right horn in the right uterine horn placentas appeared 
ischemic changes and morphological picture is not 
fundamentally different from the placentas condition 
in a group of animals with the simulation of a 
reduced blood flow in both uterine horns 
Б А 
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Figure 1.5. Pathological changes in placental ischemia. A – a general view with extensive necrosis and hemorrhage in the 
labyrinth zone (LZ), B – and hemorrhagic necrosis of the lake in the LZ, B – a major focus of purulent detsiduita, tissue 
separation at the boundary of the placenta and the uterine wall. H & E stain. Fig-. X50 (A), X200 (B, C) 
Integral characteristics of scoring changes in 
morphological parameters for modeling ADMA-like 
preeclampsia and simulate the reduced blood flow to 
the uterus is presented in Table. 1.1. 
Table 1.1 
Values of morphological and functional parameters in pregnant rats at modeling ADMA-like preeclampsia  
and reduced blood flow in the uterus , (M ± m; n = 10) 
Group 
Index 
Pregnant 
Pregnant intact + 
L-NAME 
Pregnant 
(reduced blood flow to 
the uterine horns 2) 
Pregnant (reduced blood 
flow in the right uterine 
horn) 
SBP mm Hg. 134,5±2,3y 186,3±7* 155,4±3,6* 138,8±4,4y 
DBP, mm Hg. 92,0±2,1y 145,0±5,0* 109,3±5,7* 89,8±5,8y 
CED, cond. u 1,10±0,11y 3,12±0,17* 2,02±0,23* 1,29±0,08y 
microcirculation, 
per. u 
446,3±27,5y 218,3±13,7* 229,7±9,9* 204,4±14,3*R 
309,0±15,8*yL 
NOx, umol/dL 2,28±0,11y 1,28±0,08* 2,12±0,11y 2,15±0,09y 
eNOS, % 113,2±5,1y 68,5±3,3* 104,5±6,6y 105,4±3,2 y 
Assessment of pathomo–
rphological shanges, in points 
0-1 5-6
*
5-6
*
 5-6
*P
 
0-1
L
 
The liquid content in 
tissues gland % 
49,89±0,82y 58,09±1,73 52,86±2,66 48,78±2,00y 
Weight , g 1,73±0,06y 1,52±0,06* 1,16±0,04* 1,13±0,06*R 
1,31±0,08*L 
The growth, mm 24,59±0,42y 22,91±0,34* 20,10±0,27* 20,89±0,45*R 
22,90±0,45*L 
Height/weight 
mm/g 
14,91±0,28y 15,93±0,31* 18,25±0,55* 19,36±0,76*R 
18,63±0,68*L 
Postimplantation death,% 0 0 36,53±2,86* 34,16±3,37*R 
18,66±5,66*L 
Note: * – p <0.05 comparison with intact pregnant rats; y- at p <0.05 in comparison with pregnant rats with L-NAME, 
R- microcirculation in the right uterine horn, L – microcirculation in the left uterine horn.  
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Comparative assessment of the fruit revealed a 
decrease in fetal weight at all modeled pathological 
conditions as compared to the intact group of 
pregnant animals. In groups of animals with reduced 
uterine blood flow malnutrition fruit it was more 
pronounced compared to the group with ADMA – 
similar to preeclampsia. In addition, in animals with 
reduced uterine blood flow was observed 
postimplantation fetal death (Table 1.1.). 
Thus, a comprehensive analysis of 
morphological and functional changes in the 
simulation of various pathologies of pregnant women 
leads to the conclusion that the ADMA-like model is 
closest to the second half of pregnancy gestosis. This 
is supported by: high blood pressure, disturbance of 
the relationship vasoconstrictor and vasodilating 
mechanisms, reduction of microcirculation in the 
placenta, increasing proteinuria, violation of NO-
synthesizing endothelial function, a set of 
morphological changes in the kidney and placenta, 
that was the reason for using it as a base model. 
2. RESEARCH EFFICIENCY OF 
PHARMACOLOGICAL AGENTS AFFECTING 
THE WAY L-ARGININE – NO – CGMP, THE 
CORRECTION OF ADMA-LIKE 
PREECLAMPSIA 
Investigation of the effectiveness of 
pharmacological agents that affect the way L-arginine – 
NO – cGMP: tetrahydrobiopterin (BH4), a selective 
inhibitor of arginase 2 (ZB49-0010) and a PDE-5 
inhibitor tadalafil in the correction of ADMA-like 
preeclampsia showed a statistically significant reduction 
in blood pressure under the influence BH4, tadalafil and 
drug included with standard therapy of preeclampsia 
methyldopa and improving endothelial dysfunction 
(CED) under the influence of all studied 
pharmacological agents affect the way L-arginine – NO 
– cGMP (Table 2.1.).
When microcirculation research in placenta 
were detected its improvement under the influence 
of tetrahydrobiopterin, a selective inhibitor of 
arginase 2 and tadalafil (Table 2.1.). In addition, 
under the influence of pharmacological agents that 
affect the way L-arginine – NO – cGMP 
methyldopa and a decrease in proteinuria (see 
Table 2.2.). 
In the study of the effect of 
tetrahydrobiopterin, ZB49-0010 and tadalafil on 
the NO-synthesizing endothelial function in the 
correction of ADMA-like preeclampsia was found 
a statistically significant improvement (p <0,05) 
under the influence of methyldopa, 
tetrahydrobiopterin and ZB49-0010 (Fig. 2.1). This 
applies to both end metabolites content NO, and 
the level of expression of eNOS. 
Morphological and immunohistochemical 
study revealed kidney and placenta protective 
effect of the application of methyldopa and 
pharmacological agents that affect the metabolic 
pathway of L-arginine – NO – cGMP, which 
resulted in an integrated approach to the 
assessment of the group intact pregnant animals 
(Table 2.3.). 
Table 2.1 
Effect of pharmacological agents that affect the way L-arginine – of NO – cGMP in the blood pressure, CED  
and microcirculation in the placenta in the correction of ADMA-like preeclampsia in rats (M ± m; n = 10) 
Note: * – p <0,05 – compared to intact; y – p <0.05 – in comparison with L-NAME. 
  Group 
Index 
SBP, 
mmHg. 
DBP, 
mmHg. 
CED , 
cond. u 
Microcirculation 
intact 134,5±2,3y 92,0±2,1y 1,10±0,11y 446,3±27,5y 
L-NAME 186,3±7* 145,0±5,0* 3,12±0,17* 218,3±13,7* 
L-NAME + methyldopa (2 x 0,43) 
mg / kg / day 
135,8±2,9y 103,8±3,8y 3,16±0,33* 248,4±10,7* 
L-NAME + tetrahydro-biopterin 
(10 mg / kg) 
157,4±7,9*y 116,7±8,8*y 1,73±0,24*y 402,0±26,2y 
L-NAME + ZB49-0010 (5 mg / kg) 192,5±8,7* 150,2±6,7* 1,49±0,14y 435,4±27,4y 
L-NAME + tadalafil (0.9 mg / kg) 149,7±2,2y 97,6±3,2y 1,85±0,08*y 398,7±24,9y 
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Table 2.2  
Effect of pharmacological agents that affect the way L-arginine – NO – cGMP values of parameters a 12-hour 
proteinuria and urine output correction ADMA-like preeclampsia (M ± m; n = 10) 
                                          Group  
Index 
Number of 12-hour urine 
(mL) 
Proteinuria 
(G / l) 
intact pregnant 5,8±0,3 0,93±0,06у 
L-NAME 5,6±0,3 2,04±0,22* 
L-NAME + methyldopa (2 x 0,43) mg / kg / day 5,4±0,3 1,45±0,14* у 
L-NAME + tetrahydrobiopterin (10 mg / kg) 5,6±0,3 1,16±0,09у 
L-NAME + ZB49-0010 (5 mg / kg) 5,6±0,3 1,19±0,10 у 
L-NAME + tadalafil (0.9 mg / kg) 5,7±0,3 0,99±0,05у 
 
Note: * – p <0,05 – compared with intact pregnant animals; y – p <0.05 – compared with pregnant females receiving L-
NAME. 
  
Note: * – p <0.05 compared with intact pregnant rats; Y- p <0.05 compared with the group of pregnant animals 
treated with L-NAME. 
 
Figure 2.1. Study of the influence on NOx concentration in plasma and the expression of eNOS pharmacological agents  
that affect the way L-arginine – of NO – cGMP in the correction of ADMA-like preeclampsia 
Table 2.3 
Effect of pharmacological agents that affect the way L-arginine – NO – cGMP to integral evaluation of the complex 
pathological changes in the kidney and placenta eNOS expression and the correction ADMA-like preeclampsia (n = 10) 
 
A series of experiments 
Comprehensive assessment 
in points 
The expression of eNOS 
placenta, % 
Intact pregnant females 0-1 5,4±0,21 
L-NAME 5-6
*
 0,04±0,01* 
L-NAME + methyldopa (2 x 0,43) mg / kg / day 3
*
 2,07±0,16* 
L-NAME + tetrahydrobiopterin (10 mg / kg) 2-3
*
 4,01±0,26 
L-NAME + ZB49-0010 (5 mg / kg) 2
*
 4,45±0,21 
L-NAME + tadalafil (0.9 mg / kg) 3
*
 5,04±0,26 
Note. * – P <0,05 compared with intact pregnant females. 
 
 
Microscopic study of the kidneys of animals 
treated, showed the same kind of picture that is 
sharply different from the control group of pregnant 
rats. Small artery kidney cortex with signs of mild 
hypertrophy of the muscular layer. The capillaries 
glomeruli congested, thickened basement membranes 
is not a symptom of "wire loops" were absent. 
Mesangial significant reaction was observed. Thus, 
the average number of cells per glomerulus in the 
group using Tadalafil was 39.80 ± 2.31 (40.70 ± 3.80 
normally). 
 
Morphology of the placenta at the L-NAME-
induced preeclampsia, the treatment of methyldopa 
and pharmacological agents affect the metabolic 
pathway of L-arginine – NO – cGMP, I approached 
the group of intact animals. It noted monomorphic 
layer structure of the placenta without focal 
destructive changes, mild hyperemia spongy layer. 
On the outer surface of the placenta were observed 
traces of fibrin deposits. 
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Thus, the use of tetrahydrobiopterin, a selective 
inhibitor of arginase 2 and tadalafil has a marked 
protective effect on the model of ADMA-like 
preeclampsia, which was reflected in a statistically 
significant antihypertensive effect, reducing the rate 
of endothelial dysfunction (CED), the prevention of 
reduction of microcirculation in the placenta and in 
full prevention NOx reduction of nitrite ions and 
eNOS expression under the influence of tadalafil. At 
the same time, the results of the placenta urine 
studies showed a reduction in proteinuria. 
Morphological studies of kidney and placenta in 
these groups showed maximal approach to histology 
group intact pregnant animals. 
The results of correction of morphological and 
functional disorders of the cardiovascular system in 
such of ADMA-eclampsia suggest a promising 
approach for the treatment and prevention of 
preeclampsia aimed at overcoming of ADMA-
mediated inhibition of eNOS and correction caused 
by its pathophysiological changes. 
3. RESEARCH EFFICIENCY SHORT
EPISODE ISCHEMIA-REPERFUSION AND 
RECOMBINANT ERYTHROPOIETIN OF 
ADMA-IN LIKE PREECLAMPSIA AND ROLE 
AND INOS ATP-DEPENDENT K + CHANNELS 
IN THE REALIZATION OF THEIR POSITIVE 
EFFECT 
Investigation of the effectiveness of short 
episodes of ischemia-reperfusion, and recombinant 
erythropoietin for the correction of morphological 
and functional disorders of ADMA-while similar 
preeclampsia 
Playing a single ischemic episode, for 90 
minutes before removing the samples did not lead to 
any significant change in blood pressure. 
10x playback ischemic episode and recombinant 
erythropoietin administration resulted in a statistically 
significant reduction in blood pressure: Systolic to 
141.6 ± 5.5 and 143.5 ± 4.0 mmHg, diastolic to 104.2 ± 
5.7 and 98,1 ± 5,9 mm Hg (P <0.05), respectively 
(Table. 3.1). 
Playing as a single ischemic episode in 90 
minutes to remove the samples and 10 times an 
episode of ischemia-reperfusion 10 to 20 days of 
gestation, and the introduction of recombinant 
erythropoietin resulted in normalization of relations 
between vasodilating and vasoconstrictor responses 
in of ADMA-like preeclampsia, as evidenced by 
CED reduction to 1,52 ± 0,09, 1,56 ± 0,13 and 1,67 ± 
0,15 mustache. u, respectively (Table. 3.1). 
It is noteworthy that a single playback of ischemia-
reperfusion episodes decreased CED on a background 
of L-NAME-induced pathology, without affecting 
blood pressure. This is indicative of the distinguishing 
features of the mechanisms of action of single and 
multiple play episodes of ischemia-reperfusion and their 
different effects on the process involved in the 
pathogenic elements of humoral and neurogenic 
contours regulation of the circulatory system. 
Playing a single, 10-fold episode ischemia-
reperfusion and administration of recombinant 
erythropoietin caused a significant improvement in 
microcirculation to 327,3 ± 17,2, 339,6 ± 20,4 and 
296,6 ± 27,1 cond. u, respectively, which was 
significantly higher than that of pregnant females 
with preeclampsia (p <0,05). 
Playing 10-multiple episodes of ischemia-
reperfusion 10 to 20 hours and the introduction of a 
recombinant erythropoietin in pregnant animals with 
simulation of ADMA-like preeclampsia indicators 
normalized protein in the urine, the values of which 
do not go beyond the norm and amounted to 1,02 ± 
0,04 and 1 01 ± 0,06 g / l, respectively, is statistically 
distinguishable (p <0.05) compared to untreated 
group of animals pregnant (Table 3.2.). 
Effect of short episodes of ischemia-reperfusion, 
and recombinant erythropoietin for NO-producing 
endothelial function studied on the basis of data 
eNOS expression and increase NOx content of nitrite 
ions (Fig. 3.1). It is found that after a single playback 
of ischemia-reperfusion episodes no increase 
expression or eNOS, any level of nitrite ions in the 
blood plasma. Increased expression of eNOS 
parameters occurred under the influence of 
recombinant erythropoietin, and playing back 10-fold 
episode of ischemia-reperfusion. Increased content of 
final NO metabolites in blood plasma occurred only 
at 10-fold playback episodes of ischemia-reperfusion. 
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Table 3.1 
Effect of short episodes of ischemia-reperfusion and recombinant erythropoietin on blood pressure, 
CED, and on placenta mikrocirculation (M ± m; n = 10) 
Note: SBP, DBP – systolic and diastolic blood pressure; CED – rate of endothelial dysfunction; microcirculation in 
the placenta; Ped – perfusion unit; * – P <0.05 – in comparison with a group of pregnant intact animals; y- P <0.05 – in 
comparison with a group of pregnant rats treated L-NAME.. 
Table 3.2 
 Effect of short episodes of ischemia-reperfusion and recombinant erythropoietin values of parameters a 12-hour 
proteinuria and diuresis in modeling ADMA-like preeclampsia (M ± m; n = 10) 
    Group 
Index 
Number of 12-hour 
urine (mL) 
Proteinuria 
(G / l) 
Intact 
5,8±0,3 0,93±0,06у 
L-NAME 5,6±0,3 2,04±0,22* 
L-NAME + ischemia-reperfusion (10) 5,5±0,3 1,02±0,04
у
 
L-NAME + recombinant erythropoietin (50 U / kg) 5,3±0,2 1,01±0,06у 
Note: * – p <0,05 – compared with intact pregnant animals; y – p <0.05 – compared with pregnant females receiving 
L-NAME. 
Note: * – p <0.05 comparison with intact pregnant rats; 
Y- p <0.05 compared with the group of pregnant rats treated with L-NAME. 
Figure 3.1. Effect of short episodes of ischemia-reperfusion, and recombinant erythropoietin for NOx concentration in the 
plasma and in eNOS expression in endothelial correction ADMA-like preeclampsia 
Morphologic study of kidney and placenta also 
found a protective effect of 10-fold playback ischemia-
reperfusion episodes and administration of recombinant 
erythropoietin. In animals with 10x playback of short 
episodes of ischemia-reperfusion picture dramatically 
different from the control group of pregnant rats. Small 
artery kidney cortex with mild signs of hypertrophy and 
spasm of the muscle layer. The capillaries glomeruli 
congested, thickened basement membranes is not a 
symptom of "wire loops" is missing. A notable reaction 
mesangium were observed: the average number of cells 
per glomerulus was 36.80 ± 3.16 (normally 
40.70 ± 3.80). 
Morphological examination of the placenta in 
the correction of L-NAME-induced preeclampsia 10x 
playback episode ischemia-reperfusion revealed the 
elimination of ischemic damage in the placental 
tissue (Fig. 3.3). There was a relatively even layer of 
spongy blood supply, no damage layer of giant 
trophoblast and decidua. On the outer surface of the 
placenta observed weak fibrin deposits.  
Integral characteristics of scoring morphological 
parameters and results of immunohistochemical 
study are presented in Table. 3.3, which implies that 
a 10-fold playback brief episode of ischemia-
reperfusion injury and administration of recombinant 
erythropoietin significantly reduced cumulative 
evaluation score and reduced in eNOS expression in 
placenta compared to ADMA-like preeclampsia. 
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Table 3.3 
Effect of 10 min ischemia-reperfusion episodes of pathological changes of the complex and expression 
of eNOS in modeling ADMA-like preeclampsia (n = 10) 
№ п/п A series of experiments 
Comprehensive assessment 
in points 
The expression of eNOS 
placenta, % 
1 Intact pregnant females 0-1 5,4±0,21 
2 ADMA-like preeclampsia 5-6* 0,04±0,01* 
3 L-NAME + ischemia-reperfusion (10) 2-3* 5,18+0,38 
4 L-NAME + recombinant erythropoietin (50 U / kg) 3* 5,18+0,27 
Note. * – P <0.05 compared to intact pregnant females. 
Figure 3.2. The placenta in animals with 10x playback of transient ischemic episodes on the background of ADMA-like 
preeclampsia. A – decidual layer: monomorphic structure, the absence of degenerative changes; B – even krovenapolnenie 
spongy layer; In – No degenerative changes trophoblast; Ochre. hematoxylin and eosin. Fig-. X 200 
Study the role of iNOS and ATP-sensitive K
+
 
channels in the implementation of the positive 
effects of brief ischemia-reperfusion episodes in the 
correction of ADMA-like preeclampsia 
Introduction of aminoguanidine, which is a 
selective inhibitor of iNOS, or glibenclamide, which 
is a blocker of ATP-sensitive K
+
 channels, healthy 
pregnant animals did not result in a statistically 
significant change in blood pressure, CED, 
microcirculation in the placenta and proteinuria. 
Introduction aminoguanidine or glibenclamide 
pregnant animals with experimental preeclampsia, 
the treatment of short episodes of ischemia-
reperfusion injury, resulted in the total elimination of 
their antihypertensive effect, worsened circulation in 
the placenta (Fig. 3.3), and increased to the level of 
proteinuria in untreated animals. Only CED, despite a 
statistically significant increase in its remained below 
the group of untreated animals (p <0,05). 
When administered aminoguanidine or 
glibenclamide pregnant animals fundamentally 
significant reduction of nitrite ions in the plasma and 
the activity of eNOS did not happen. When 
administered to animals with them of ADMA-like 
preeclampsia, the treatment of short episodes of 
ischemia-reperfusion, increased levels of nitrite ions 
in the blood plasma of the final metabolites of NO 
and eNOS expression under the influence of the latter 
did not occur (Fig. 3.4). 
Noteworthy is that the negative effect of 
aminoguanidine and glibenclamide on functional 
indicators only appears when you attempt to correct 
А 
Б 
В 
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the modeled pathology, indicating the important role 
of iNOS and ATP-sensitive K
+
 channels in the 
implementation endothelioprotektive effect of short 
episodes of ischemia-reperfusion. 
Morphologic kidneys and placenta study 
animals administered aminoguanidine or 
glibenclamide revealed the absence of any effect on 
their microscopic picture in the bodies that matched 
the group intact pregnant animals (0-1 points). 
Note: * – p <0.05 comparison with intact pregnant rats; 
Y- p <0.05 compared with the group of animals treated with L-NAME. 
Figure 3.3 Effect of aminoguanidine (300 mg / kg) and glibenclamide (50 mg / kg) on blood pressure, CED, micro-circulation 
in the placenta and proteinuria in the correction of ADMA-like preeclampsia short episodes of ischemia-reperfusion 
Note: * – p <0.05 comparison with intact pregnant rats; 
Y- p <0.05 compared with the group of animals treated with L-NAME. 
Figure 3.4. Effect of aminoguanidine (300mg / kg) and glibenclamide (50 mg / kg) on the NOx concentration in plasma 
and the expression of eNOS in the correction ADMA-like preeclampsia short episodes of ischemia-reperfusion 
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When administered aminoguanidine or 
glibenclamide experimental animals with 
preeclampsia, the treatment of short episodes of 
ischemia-reperfusion, there was almost complete 
elimination of the positive impact of the latter in the 
placental tissue and kidney. The kidneys were 
observed spasm and hypertrophy of the muscle layer 
of small arteries. Flattened tubular epithelium, on 
significant areas of desquamated. A notable reactions 
were observed mesangium. 
Morphological picture of the placenta villi and 
ischemia manifested intervilleznyh spaces and 
desquamation of the endothelium in the vessels of the 
placenta. There have been foci of necrosis of 
decidual cells in the placental tissue. On the outer 
surface of the placenta was observed massive 
deposits of fibrin. 
Integral characteristics of scoring morphological 
parameters and results of immunohistochemical study 
are presented in Table. 3.4, from which it follows that a 
10-fold reproduction of short episodes of ischemia-
reperfusion on the background of aminoguanidine or 
glibenclamide positive effect on the morphological and 
functional disorders of ADMA-while such did not have 
preeclampsia. 
Table 3.4 
Effect of aminoguanidine and glibenklamina on 
complex pathological changes and the expression  
of eNOS in the correction of short episodes of ischemia-
reperfusion of ADMA-like preeclampsia (n = 10) 
№ 
A series of 
experiments 
Comprehensive 
assessment in 
points 
eNOS 
expression 
in the 
placenta,% 
1 Intact pregnant 
females 
0-1 5,4±0,21 
2 ADMA-like 
preeclampsia 
5-6* 0,04±0,01* 
3 L-NAME + 
ischemia-
reperfusion (10) 
2-3* 5,18±0,38 
4 L-NAME + 
Ischemia-
reperfusion injury 
(10) + 
aminoguanidine 
(300mg / kg) 
5-6* 0,03±0,01* 
5 L-NAME + 
Ischemia-
reperfusion injury 
(10) + 
Glibenclamide (50 
mg / kg) 
5-6* 0,04±0,01* 
Note. * – P <0.05 compared to intact pregnant 
females. 
Thus, a single and 10x playback of short ischemic 
episodes and the introduction of recombinant 
erythropoietin has shown marked endotelioprotektivnoe 
effect on the model of ADMA-like preeclampsia, which 
was reflected in the strengthening of endothelium-
dependent relaxation of blood vessels and reducing the 
rate of endothelial dysfunction CED to the level of 
intact animals, as well as in reducing violations 
microcirculation in the placenta. In addition, a 10-fold 
reproduction of short ischemic episodes and the 
introduction of recombinant erythropoietin resulted in a 
decrease in blood pressure, normalization of 
proteinuria, restore function NO-producing system. 
Morphological study revealed the prevention of 
destructive phenomena ischemic, caused by the 
introduction of L-NAME when playing 10-fold 
ischemic episodes and the introduction of recombinant 
erythropoietin. However, complete normalization of 
morphological picture in the kidney and placenta did 
not come. 
It should be noted that the effects of a single 
playback and 10x playback ischemic episodes NO-
synthesizing function multidirectional. This fact 
shows the different mechanisms for the 
implementation of their action 
endotelioprotektivnogo. 
In the presented experiments showed that the 
administration of aminoguanidine, an inhibitor of 
iNOS, or glibenclamide, which is a blocker of ATP-
sensitive K + channels, the experimental animals of 
ADMA-like preeclampsia, treatment playback 
ischemia-reperfusion episodes, almost completely 
eliminates the positive effect of the latter. This is 
manifested in the removal of gipotezivnogo effect, 
reducing the severity of a positive effect on 
endothelial function, reduction of microcirculation in 
the placental tissue and indicators of endothelial NO-
producing function to the level of untreated animals, 
as well as in the restoration of destructive damage to 
the placental tissue and ischemic kidneys. This 
demonstrates the important role of iNOS and ATP-
sensitive K + channels in the implementation of the 
protective effects of ischemia-reperfusion episodes in 
the correction of ADMA-like preeclampsia in the 
experiment. 
4. STUDY OF EFFICIENCY 
ERYTHROMYCIN AND AZITHROMYCIN IN 
ADMA-LIKE PREECLAMPSIA  
Introduction of azithromycin (30 mg / kg) 
resulted in a statistically significant reduction in both 
systolic and diastolic blood pressure in animals with 
experimental ADMA-like preeclampsia (Fig. 4.1). 
Introduction erythromycin (30 mg / kg) did not have 
any significant effect on these parameters. Both drugs 
approximately equally CED significantly reduced to 
1.88 ± 0.16 and 1.82 ± 0.09, respectively (p <0.05), 
whereas in the group of untreated pregnant rats given 
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L-NAME, it was 3,12 ± 0,17. However, the target 
level of reduction of CED is not reached. 
Course administration of erythromycin and 
azithromycin caused a significant improvement in 
microcirculation to 381,9 ± 16,6 and 362,1 ± 16,7 
perfusion units, respectively, which was significantly 
higher than that of pregnant females with preeclampsia 
(p <0,05), and statistically It did not differ from the 
values of the microcirculation in intact pregnant rats. In 
addition, there was a decrease in urine protein to the 
level of intact animals (Fig. 4.1). 
Introduction of erythromycin and azithromycin 
caused improvement in NO-synthesizing endothelial 
function, which resulted in an increase in the level of 
nitrite ions in the plasma by the action of erythromycin 
and statistically significant increase in eNOS expression 
under the influence of both drugs (Fig. 4.2). 
A morphological study of the kidney and the 
placenta also found a protective effect of 
erythromycin and azithromycin. The renal vessels in 
animals treated with L-NAME during treatment with 
erythromycin and azithromycin, the pattern was 
different from the control group of pregnant rats. The 
most pronounced beneficial effects of the therapy 
was observed in the group of animals with the use of 
azithromycin. Small artery kidney cortex with 
moderate signs of hypertrophy of the muscular layer. 
The capillaries glomeruli congested, slightly 
thickened basement membranes, symptom "wire 
loops" is missing. A notable reaction mesangium 
were observed: the average number of cells per 
glomerulus was 39.40 ± 2.74 and 39.30 ± 2.55 
respectively (normal 40.70 ± 3.80). 
Morphological examination of the placenta in 
the correction of erythromycin and azithromycin L-
NAME-induced preeclampsia showed the same type 
of histology in both groups, but more positive effects 
were found in a group of animals receiving 
azithromycin. Placenta without pathological changes, 
naps and intervilleznye congested space. There are 
signs of ischemia of the functional nature of the 
placenta. On the outer surface of the placenta fibrin 
deposits were observed. 
Notes: * – p <0.05 comparison with intact pregnant rats; 
Y- p <0.05 compared with the group of pregnant animals treated with L-NAME. 
Figure 4.1. Effect of erythromycin (30 mg / kg) and azithromycin (30 mg / kg) on blood pressure values, CED, 
micro-circulation in the placenta and proteinuria in the correction of ADMA-like preeclampsia 
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Note: * – p <0.05 compared to intact rat; Y- p <0.05 compared with the group of animals treated with L-NAME 
Figure 4.2. Effect of erythromycin (30 mg / kg) and azithromycin (30 mg / kg) on the NOx concentration in the plasma and in 
eNOS expression in endothelial correction ADMA-like preeclampsia. 
Integral characteristics of scoring morphological 
parameters and results of immunohistochemical 
study are presented in Table. 4.1, which implies that 
erythromycin and azithromycin significantly reduced 
scores in the evaluation of the integral (3.4) 
compared to ADMA-like preeclampsia and increased 
eNOS expression in placental vascular endothelium. 
Thus, erythromycin and azithromycin, 30 mg 
/ kg showed a clear endothelioprotektive action 
model L-NAME-induced preeclampsia, as 
manifested in the reduction rate of endothelial 
dysfunction up to the level of intact animals, 
improving microcirculation in the placenta, and to 
reduce the decrease eNOS expression on background 
complete prevention of proteinuria. Additionally, 
azithromycin showed moderate hypotensive effect, 
erythromycin reduced drop stable metabolites in 
plasma NOx. Morphological studies have found a 
decrease under the influence of erythromycin and 
azithromycin in the indicated doses of disorders of 
kidney and ischemic changes in the placenta, not 
reaching the damage to structures. 
5. STUDY THE EFFECTIVENESS OF
VITAMIN B9, COMBINING THE USE OF 
VITAMIN B9 AND B6, VITAMIN-MINERAL 
COMPLEX "COMPLIVIT® TRIMESTRUM 
TRIMESTER 2" AND "COMPLIVIT® 
TRIMESTRUM TRIMESTER 3" WITH ADMA-
LIKE PREECLAMPSIA 
Introduction to the study drugs: folic acid, a 
combination of folic acid and vitamin B6, 
multivitamin-mineral complexes "Complivit
®
 
trimestrum Trimester 2" and " Complivit
®
 trimestrum 
Trimester 3" did not have any significant effect on 
blood pressure in the background of the simulated 
pilot of ADMA-like preeclampsia (Fig. 5.1).  
Introduction of folic acid alone does not 
result in correction of CED. The introduction of folic 
acid in combination with vitamin B6, as well as both 
multivitamin-mineral complexes led to an 
improvement in endothelial function, which resulted 
in a statistically significant reduction in CED. 
Improvement of microcirculation in the placenta 
occurred in all treatment groups (Fig. 5.1). 
The use of vitamin and mineral complexes 
"Complivit
®
 trimestrum Trimester 2" and 
"Complivit
®
 trimestrum trimester 3" in pregnant 
animals with simulation L-NAME-induced 
preeclampsia statistically significantly reduced the 
amount of protein in the urine, bringing its value in 
the last group of animals to the value of intact 
animals . Using a combination of folic acid and folic 
acid and vitamin B6 are not resulted in a statistically 
significant reduction in proteinuria pathology in this 
model (Fig. 5.1). 
Investigation of the effect of vitamin B9, 
combined use of vitamins B6 and B9, drugs 
"Complivit
®
 trimestrum Trimester 2" and 
"Complivit
®
 trimestrum trimester 3" to the NO-
synthesizing endothelial function in the correction of 
ADMA-like preeclampsia showed that the use of 
multivitamin-mineral preparations "Complivit
®
 
trimestrum trimester 2" and "Complivit
®
 trimestrum 
trimexter 3" significantly increased the concentration 
of nitrite ions (Fig. 5.2). Introduction of folic acid 
and its combination with Vitamin B6 not result in a 
statistically significant increase in the concentration 
of nitrite ions in the blood plasma of animals with 
ADMA-like preeclampsia. 
Table 4.1 
Effect of erythromycin and azithromycin in the complex 
pathological changes and the expression of eNOS in 
placenta in modeling ADMA-like preeclampsia (n = 10) 
№ A series of experiments 
Comprehen
sive 
assessment 
in points 
eNOS 
expression 
in the 
placenta,% 
1 Intact pregnant females 0-1 5,4±0,21 
2 L-NAME-induced 
preeclampsia 
5-6* 0,04±0,01* 
3 L-NAME + erythromycin 
(30 mg / kg) 
3-4* 3,77±0,12* 
4 L-NAME + azithromycin 
(30 mg / kg) 
3* 4,28±0,21* 
Note. * – P <0.05 as compared with intact 
pregnant females. 
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Note: Hereafter – СTr2Tr – «Complivit® trimestrum Trimester 2"; СTr3Tr – «Complivit® trimestrum trimester 3"; * – 
P <0.05 comparison with intact pregnant rats; Y- p <0.05 compared with the group of pregnant animals treated with L-NAME. 
Figure 5.1. Impact of the B9 vitamin (0,2mg / kg) combined use of vitamins B9 (0,2 mg / kg) and B6 (2 mg / kg) of drugs 
"Complivit
®
 trimestrum 2 Trimester" (0.084 tab/kg) "Complivit
®
 trimestrum 3 trimester" (Table 0.084 tab/kg) on blood 
pressure, CED, micro-circulation in the placenta and proteinuria in the correction of ADMA-like preeclampsia 
Dynamic expression of eNOS in the application of indicators described in this chapter preparations wore the 
same character as the concentration of stable NO metabolites (Fig. 5.2). There was a statistically significant 
increase in eNOS expression indices only in groups of animals treated with multivitamin-mineral preparations 
"Complivit
®
 trimestrum Trimester 2" and "Complivit
®
 trimestrum trimester 3" 
Note: Hereafter – СTr2Tr – «Complivit® trimestrum Trimester 2"; СTr3Tr – «Complivit® trimestrum trimester 3"; * – 
P <0.05 comparison with intact pregnant rats; Y- p <0.05 compared with the group of pregnant animals treated with L-NAME. 
Figure 5.2.  Effect of vitamin B9 (0,2 mg / kg), the combined use of vitamins B9 (0,2 mg / kg) and B6 (2 mg / kg) of drugs 
"Complivit
®
 trimestrum Trimester 2" ( 0.084 tab/kg) and "Complivit
®
 trimestrum 3 trimester" (0.084 tab/kg) in the NOx 
concentration in plasma and the expression of eNOS in the correction of ADMA-like preeclampsia 
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A morphological study of the kidney and the 
placenta was found that administration of folic acid 
and its combination with vitamin B6 did not result in 
improvement of histological kidney and placenta. 
With the introduction of vitamin and mineral 
complexes "Complivit
®
 trimestrum Trimester 2" and 
"Complivit
®
 trimestrum Trimester 3" observed 
moderately positive dynamics in the kidney and in 
placenta (Table. 5.1). In addition, there was increase 
in eNOS expression in placental vascular 
endothelium. 
Thus, the data presented studies indicate that the 
minimum protective properties have been identified 
by using folic acid as monotherapy and when 
combined with its use of vitamin B6. Intensity of 
positive effects from the use of multivitamin-mineral 
preparations "Complivit
®
 trimestrum Trimester 2" 
and "Complivit
®
 trimestrum trimester 3" bore 
significant character and manifested in the 
improvement of endothelial function, increase 
microcirculation indices in the placenta and increase 
of NO-synthesizing endothelial function, reduction of 
proteinuria and positive dynamics of the 
morphological picture in the kidney and placenta. 
Table 5.1 
Effect of vitamin B9, combined use of vitamins B6 and 
B9, drugs "Complivit
®
 trimestrum Trimester 2" and 
"Complivit
®
 trimestrum trimester 3" in the complex 
pathological changes and the expression of eNOS in the 
correction of ADMA-like preeclampsia (n = 10) 
№ 
A series of 
experiments 
Comprehensive 
assessment in 
points 
eNOS 
expression 
in the 
placenta,% 
1 Intact pregnant 
females 
0-1 5,4±0,21 
2 L-NAME 5-6* 0,04±0,01* 
3 L-NAME + B9 (0,2 
mg/kg) 
5-6* 0,04±0,01* 
4 L-NAME + B9 (0,2 
mg/kg)+ 
B6 (2 mg/kg) 
5-6* 0,03±0,01* 
5 L-NAME + СTr2Tr 
(0.084 tab/kg) 
4* 2,02±0,12* 
6 L-NAME + СTr3Tr 
(0.084 tab/kg) 
4* 1,83,±0,21* 
Note. * – P <0.05 compared to intact pregnant 
females. 
CONCLUSION. 
Comparative aspect analyzing the obtained data 
using an integrated indicator criterion morphological 
changes, it should be noted that the use of 
pharmacological agents that affect the path of L-
arginine was the most effective – NO – cGMP (Table 
6.1.). This can be explained by a direct effect on the 
main pathogenesis. In addition, special attention should 
be data obtained by correcting the experimental 
preeclampsia short episodes of ischemia-reperfusion 
and recombinant erythropoietin. In clinical situations 
where significantly increases the role of ischemic events 
in the placenta of their use will be increasingly 
important. 
Less pronounced therapeutic effect of 
macrolides and multivitamin-mineral complexes due 
to their influence on the part of the mediated 
pathogenesis. However, this is not how does not 
reduce the significance of the study. Both of these 
groups of drugs can not be regarded as a drug of 
choice for targeted treatment of preeclampsia, but 
that they have of the pleiotropic effects of vitamin 
increases the relevance of a balanced diet during 
pregnancy, and in case of need for antibiotic 
macrolides become an important property for the 
benefit of their choice. 
Table 6.1 
Integrated assessment of complex pathological  
changes in the kidney and placenta in the correction 
of ADMA-like preeclampsia (n = 10) 
A series of experiments 
Comprehensive 
assessment in 
points 
Intact pregnant females 0-1 
L-NAME 5-6* 
L-NAME + tetrahydrobiopterin (10 mg / 
kg) 
2-3* 
L-NAME + ZB49-0010 (5 mg / kg) 2* 
L-NAME + tadalafil (0.9 mg / kg) 3* 
L-NAME + ischemia-reperfusion (10) 2-3* 
L-NAME + recombinant erythropoietin 
(50 U / kg) 
3* 
L-NAME + erythromycin (30 mg / kg) 3-4* 
L-NAME + azithromycin (30 mg / kg) 3* 
L-NAME + СTr2Tr (0.084 tab/kg) 4* 
L-NAME + СTr3Tr (0.084 tab/kg) 4* 
Note: * – p <0,05 compared with intact pregnant 
females; 
In conclusion, it should be noted that the results 
of this work provide experimental basis for new 
approaches of prevention and treatment of 
preeclampsia pharmacological agents designed to 
overcome or compensate ADMA-mediated inhibition 
of NO-synthesizing endothelial function, as well as 
the activation of biological processes underlying 
mechanism of the positive effects of ischemic 
preconditioning. 
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